FDA and White House clash over regulation

The Food and Drug Administration and the White House have been clashing on numerous regulatory issues, this article details. "The politicization of the FDA could hurt not only consumer protection but industry profits as well," said Harvard University professor Daniel Carpenter. "If this trend continues, one could easily see major government purchasing programs in Europe, India, China and elsewhere saying, 'We're not going to follow FDA recommendations anymore.' "

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief: